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ABSTRACT 
 
Background – Whether, and for how long, conservative management is superior to treatment of 
unruptured brain arteriovenous malformations (bAVMs) remains is uncertain. 
Methods – In a prospective, national population-based study to identify and validate unruptured 
bAVM diagnoses first made in over 10 year period (1999-2003 or & 2006-2010) in Scottish adult 
residents, we used multiple sources to assess handicap and to identify and validate outcome 
events over 12 years of prospective follow-up. We compared the effects of conservative 
management versus bAVM treatment on outcome using Cox regression analyses, with 
multivariable adjustment for prognostic factors and baseline imbalances if hazards were 
proportional. 
Results – Of 204 adults, 101 underwent bAVM treatment; and they were younger, more likely to 
present with seizure(s), and less likely to have large bAVMs than adults managed conservatively. 
The rate of progression to Oxford Handicap Scale score ≥2 for at least two successive years was 
lower with conservative management during four years of follow-up (36 versus 39 events, 
adjusted hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.35 to 0.99), but rates were similar 
thereafter. The rate of non-fatal symptomatic stroke or death due to bAVM, associated arterial 
aneurysm or treatment, was lower with conservative management during 12 years of follow-up 
(14 versus 38 events, adjusted HR 0.37, 95% CI 0.19 to 0.72). 
Conclusions – Conservative management of unruptured bAVMs is superior to bAVM treatment 
over at least four years. Longer-term follow-up must is needed to determine whether this 
difference is sustained. (Funded by the UK MRC, Stroke Association, and Chief Scientist Office of 
the Scottish Government) 
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INTRODUCTION 
 
Unruptured brain arteriovenous malformations (bAVM) and their associated arterial aneurysms 
(bAVM) have a low annual risk of intracranial hemorrhage,1 which has a one year case fatality of 
12%,2 although most studies of untreated clinical course of unruptured bAVM untreated clinical 
course have reported risks over less than 10 years.3 The risk of hemorrhage seems higher if an 
unruptured bAVM has a deep location, exclusively deep venous drainage, or associated 
aneurysms;1 however, more than three-quarters of affected adults do not have these risk factors.4 
 
Treatment by neurosurgical excision, endovascular embolization, or stereotactic radiosurgery can 
be used alone, or in combination, to obliterate bAVMs or their associated arterial aneurysms, 
dependent on their vascular anatomy.5 Because bAVM treatments have complications6 and 
unruptured bAVM [untreated] clinical course can be benign,1,3 some patients choose conservative 
management (without bAVM treatment). However, uUnruptured bAVM treatment has been 
compared with conservative management in a concurrent control group in just one ongoing 
randomized trial7,8 and only a few observational studies, which have shown harm from bAVM 
treatment in the short-term.4,9 Consequently, the best management strategy is uncertain10 and 
guidelines endorse both treatment and conservative management of unruptured bAVMs.11,12 
 
Therefore, we began a prospective, population-based cohort study in 1999 to assess the long-term 
outcome for adults affected by bAVM, with or without bAVM treatment, in everyday clinical 
practice.13,14 Such non-randomized observational studies help assess the generalizability of 
randomized controlled trials,15,16 in this case ARUBA (ISRCTN44013133), which started in 2007. In a 
preliminary analysis, we found that treatment of unruptured bAVMs more than doubled the risk of 
poor outcome in comparison to conservative management over three years of follow-up.4 After 
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doubling the size of the cohort and more than doubling the duration of follow-up, we re-evaluate 
the effects of treatment and conservative management of unruptured bAVMs. 
 
METHODS 
 
The Scottish Intracranial Vascular Malformation (IVM) Study (SIVMS) is a prospective, population-
based cohort study that uses anonymized data extracts from the National Health Service Scottish 
Audit of IVMs (SAIVMs), which included adults who were aged ≥16 years and resident in Scotland 
when first diagnosed with any type of IVM in 1999-2003 or 2006-2010 (www.saivms.scot.nhs.uk). 
The audit protocol (www.saivms.scot.nhs.uk/pdf/2008_06_SAIVMs%20protocol_v2.pdf) and 
research protocol (http://docdat.ic.nhs.uk) are published. SAIVMs identified patients through 
multiple overlapping sources of case ascertainment that included a Scotland-wide collaborative 
network of neurologists, neurosurgeons, radiologists, and pathologists and central registers of 
hospital discharges and death certificates.14 
 
Eligibility criteria 
 
In this analysis, we included adults in SAIVMS with a radiographically- or pathologically-confirmed 
first-in-a-lifetime definite diagnosis of a bAVM in 1999-2003 or 2006-2010 inclusive, which was 
unruptured at presentation. We classified adults either as receiving ‘treatment’ if they had 
undergone microsurgical excision, stereotactic radiosurgery or endovascular embolisation of an 
unruptured bAVM before the end of follow-up, or as undergoing ‘conservative management’ if 
they had not; the decision to treat was left to the discretion of the patients’ doctors in clinical 
practice. 
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Diagnostic verification 
 
Four experienced neuroradiologists (PMW, JduP, JJB, RJS) verified certainty of bAVM diagnosis on 
diagnostic brain imaging and collected data on radiographic evidence of recent intracranial 
hemorrhage as well as vascular anatomy, as previously reported,4 with reference to published 
criteria and recommendations.17,18 
 
Baseline characteristics 
 
We reviewed general (family) practitioner and hospital medical records to establish demographics, 
medical histories, and the consequences of bAVM presentation on the Oxford Handicap Scale 
(OHS), which is a derivative of the modified Rankin Scale, ranging from 0 (no symptoms) to 6 
(death).19 We reviewed these medical records, brain imaging and reports of pathological 
examinations to classify the mode of bAVM presentation and clinical outcome events during 
follow-up. When assessing clinical events at presentation and during follow-up, we also classified 
whether they were definitely, possibly, or definitely not attributable to the bAVM or a treatment 
complication. We classified events as possibly attributable to the bAVM when clinical features 
were anatomically consistent with bAVM location, but another cause (e.g. ischemic stroke) was 
possible and neuroradiological investigation had identified neither bAVM hemorrhage nor an 
alternative cause. We regarded presentations as ‘incidental’ if the adult had been asymptomatic 
or if we could not definitely relate their symptoms to the underlying bAVM; we attributed 
presentations to seizure(s) if a seizure was neither symptomatic of a concomitant intracranial 
hemorrhage nor more likely to be due to another cause. 
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Follow-up 
 
The inception point (start of follow-up) for conservative management was an adult’s presentation, 
which was the date of symptom onset or medical consultation (if asymptomatic) that led to an 
investigation diagnosing the bAVM. The inception point for treatment was the date of the first 
completed treatment of an unruptured bAVM after presentation. We used uninterrupted annual 
surveillance of general family practitioner and hospital medical records, as well as annual postal 
questionnaires to general practitionersfamily doctors and consenting participants on each 
anniversary of bAVM diagnosis, to identify outcome events and assess handicap on the OHS. Two 
investigators (CPW or RA-SS) independently assessed symptomatic clinical outcome events, 
defined as previously reported,4 using all the clinical, radiographic and pathological information 
available. In attributing the mode and cause of death we reviewed death certificates, autopsy 
reports if performed, and clinical records and brain imaging if death occurred in hospital. Extent of 
bAVM obliteration was assessed from reports of brain imaging after treatment. We gave 
precedence to obliteration confirmed by catheter angiography, otherwise we relied on magnetic 
resonance angiography, and if the bAVM was not obliterated we recorded the most recent 
imaging study to assess obliteration. 
 
Statistical methods 
 
Baseline characteristics 
 
For analyses of clinical covariates, age in years at inception was a continuous variable, OHS at 
presentation was dichotomized into 0-1 versus 2-5, and mode of presentation was dichotomized 
into seizure(s) versus other (although, if following presentation a clinical event occurred which led 
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to bAVM treatment, this subsequent event became the mode of presentation in the treatment 
group). We used axial brain imaging to determine bAVM nidus location which we dichotomized 
into deep (involving the basal ganglia, internal capsule, thalamus, hypothalamus, limbic system, or 
corpus callosum) versus other, and determined surgical eloquence of nidus location according to 
the Spetzler-Martin scale.20 For adults undergoing catheter angiography, we dichotomized venous 
drainage into exclusively deep20 superficial?20 versus other and bAVM nidus maximum diameter 
into <3cm versus ≥3cm, and derived the Spetzler-Martin grade.20 
 
Follow-up 
 
The primary outcome was death of any cause or the first occurrence of handicap (OHS 2-5, 
signifying, “some restrictions to lifestyle, but the patient can look after themselves” or worse) 
sustained for at least two successive years after inception (i.e. not including baseline OHS). The 
secondary outcome was non-fatal symptomatic stroke (intracranial hemorrhage, cerebral 
infarction, or focal neurological deficit persisting or progressing for >24 hours) or death due to the 
bAVM, an associated arterial aneurysm, or their treatment. 
 
Sample size 
 
Sample size was determined by completion of recruitment of a ten-year inception cohort and the 
accumulation of sufficient primary and secondary outcomes to enable us to adjust the effects of 
conservative management for important covariates in multivariable analyses.21 
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Analytical methods 
 
RA-SS conducted analyses according to a statistical analysis plan approved by the Steering 
Committee before data extraction (www.saivms.scot.nhs.uk/pdf/resPaper/2013_07_05_SAP.pdf). 
Completeness of follow-up data was quantified as a proportion of all the potential follow-up time 
that could have been accrued prior to death or the last available follow-up.22 Survival analyses of 
time to first event started at inception and stopped at the date of the first outcome or the date of 
censoring, whichever occurred sooner. For the primary outcome, censoring occurred at last 
available follow-up, or fist completed treatment for the conservatively managed group (except for 
adults with bAVMs that bled between presentation and treatment, who remained in the 
conservative management group). For the secondary outcome, censoring occurred at last available 
follow-up or death (possibly or definitely not attributable to bAVM), or at first completed 
treatment for the conservatively managed group. 
 
Bivariate analyses were performed using life tables and Kaplan-Meier estimates to analyze follow-
up data accrued by 12 years (when ~10% of the cohort remained under follow-up23) with 
differences between treatment and conservative management determined by the log-rank test 
and hazard ratio (HR) from Cox regression, with treatment as the referent category. Because we 
expected baseline imbalances4 that would affect outcome, we pre-specified multivariable analyses 
to adjust HRs when proportional hazards assumptions were satisfied.24 Covariates were selected in 
order from the following list without lowering the number of outcomes per covariate below ten21: 
clinical influences on functional outcome (age at inception, mode of clinical presentation,25 and 
baseline OHS score [for the primary outcome only]) and vascular anatomy that influences either 
the risk of bAVM hemorrhage (bAVM nidus location and bAVM venous drainage pattern1) or the 
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risk of bAVM treatment (maximum bAVM nidus diameter4,20). Covariates were entered 
simultaneously into the regression model. We pre-specified sensitivity analyses in our statistical 
analysis plan. 
 
RA-SS used IBM SPSS Statistics (version 19.0), Stata (version 11.2), StatsDirect (version 2.7.8), and 
Confidence Interval Analysis software to calculate: parametric statistics for between-group 
comparisons when continuous data obeyed a normal distribution and non-parametric statistics 
when they did not; exact tests in the analysis of categorical data; and HRs with Cox regression 
analyses. All reported P values are two-sided (α=0·05). 
 
Ethical approval 
 
The Multicentre Research Ethics Committee for Scotland (MREC/98/0/48) and the Fife and Forth 
Valley Research Ethics Committee (08/S0501/76) approved the conduct of observational studies 
(to which an opt-out consent policy applied) and postal questionnaire studies (which required opt-
in consent). 
 
RESULTS 
 
Baseline characteristics 
 
During 1999-2003 and 2006-2010, 213 adults were newly diagnosed in Scotland with at least one 
definite bAVM, of whom 204 were eligible for analysis (Figure 1). 103 underwent treatment of a 
bAVM or associated arterial aneurysm (five adults had non-hemorrhagic focal neurological deficits 
between presentation and the time of treatment) and 101 underwent conservative management 
Comment [PW1]: This bracketed 
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(five of whom had a bleed during follow-up and subsequently underwent treatment). Adults 
receiving treatment were younger, more likely to present with seizure(s), more likely to have a 
catheter angiogram and less likely to have a maximum bAVM diameter >6cm (Table 1). 
 
Conservative management 
 
101 adults were managed conservatively. Endovascular embolisation was attempted but did not 
proceed because of spontaneous bAVM obliteration 12 days after presentation in one adult and 
unsuitable vascular anatomy was demonstrated in another. Another second bAVM also 
spontaneously obliterated 2.4 years after presentation. 
 
bAVM treatment 
 
103 adults received their first treatment after median 13 months (inter-quartile range [IQR] 7-19, 
range 0-97) following presentation (web Figure 1).  Endovascular embolization was attempted but 
did not proceed because of unsuitable vascular anatomy in four adults (subsequently one 
underwent endovascular embolization and three underwent stereotactic radiosurgery). Two-thirds 
received a single treatment and one-third received multi-modality treatment over median 12 
months (web Figure 2 and web Table 1). 83 adults had catheter angiography and 14 had magnetic 
resonance angiography following their last treatment, demonstrating bAVM obliteration in 69% 
after single-modality and 71% following multi-modality treatments (web Table 1). Adults 
undergoing stereotactic radiosurgery had their most recent imaging study after mean 32±15 
months following their most recent treatment. 
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Outcome after bAVM treatment or conservative management 
 
We followed 204 adults with bAVM who were alive at presentation for 1,479 person-years (of 
1,567 potential person-years;, for an overall completeness of 94%22). The median duration of 
follow-up was longer after treatment (9.4 years, IQR 5.0-11.9) than during conservative 
management (5.2 years, IQR 3.0-9.7; p=0.002) because three-quarters75% of the 41 deaths 
occurred during conservative management (Figure 1 and web Figure 3). 
 
For the primary outcome, the proportional hazards assumption was met over the first four years 
of follow-up (which was when and most of the outcome events occurred).; Dduring this time the 
rate of progression to the primary outcome was lower during conservative management than 
after treatment (adjusted HR 0.59, 95% confidence interval [CI] 0.35-0.99; Table 2 and Figure 2), 
but rates were not different thereafter (4-8 years adjusted HR 1.07, 95% CI 0.37-3.16; 8-12 years 
adjusted HR 4.70, 95% CI 0.29-77.42). Over 12 years, the rate of death was higher during 
conservative management than after treatment (HR 3.64, 95% CI 1.78-7.43; web Figure 3).,This 
was not due to deathsun related to bAVM or treatment (log-rank p=0.29) but due to deaths of 
from other causes (log-rank p<0.001); these differences disappeared after age-adjustment (web 
Table 2). 
 
The rate of progression to the secondary outcome was lower during conservative management 
than after treatment over 12 years of follow-up (adjusted HR 0.37, 95% CI 0.19-0.72; Table 2 and 
Figure 3), because of symptomatic strokes due to treatment (Figure 1). After these first events, 
there were 12 more secondary outcomes in the treatment group, and only one during 
conservative management. 
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Sensitivity and supplementary analyses 
 
In pre-specified sensitivity analyses addressing outcomes before bAVM treatment, the effect of 
conservative management remained the same for the primary outcome (adjusted HR 0.58, 95% CI 
0.34-0.99 over four years) and for the secondary outcome whether including pre-treatment 
clinical course in the conservative management group (unadjusted HR 0.27, 95% CI 0.16-0.47), 
including pre-treatment clinical course in the treatment group (adjusted HR 0.50, 95% CI 0.25-
0.98),26 or including secondary outcomes that were possibly due to the bAVM (adjusted HR 0.43, 
95% CI 0.23-0.78). Post-hoc analyses restricted to adults who were OHS 0-1 at baseline did not 
change the effect of conservative management on the primary outcome (adjusted HR 0.42, 95% CI 
0.20-0.89 over four years) or secondary outcome (adjusted HR 0.35, 95% CI 0.14-0.87), and the 
direction of effect on primary and secondary outcomes remained the same in all Spetzler-Martin 
grades, although HRs were not statistically significant (data not shown). 
 
DISCUSSION 
 
In a prospective, population-based inception cohort study of adults with unruptured bAVM, we 
found that conservative management was associated with a lower rate of progression to sustained 
handicap over four years, and a lower risk of bAVM-related symptomatic stroke or death over 12 
years despite having an older population with larger bAVMs in the conservative management 
group. 
 
Comment [PW2]: ? add such a 
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These results are consistent with the initial results of ARUBA (ISRCTN44013133), the only 
randomized controlled trial assessing unruptured bAVM this management dilemma.27 The 
characteristics of the adults who received bAVM treatment in this observational study are very 
similar to the baseline characteristics of ARUBA participants,27 supporting the trial’s 
generalizability. Furthermore, the persistent difference between conservative management and 
bAVM treatment on the secondary outcome (similar to the ARUBA primary outcome) over 12 
years (more than treble the duration of follow-up in ARUBA) urges caution about the treatment of 
adults with unruptured bAVM in clinical practice, and mandates longer-term follow-up in both this 
study and ARUBA. 
 
The strengths of this study include: thorough case ascertainment14 and 94% completeness of the 
entire duration of follow-up for all adults; a population-based sampling frame to maximize 
external validity; a concurrent control group; internal validity from using independent imaging 
review and outcome assessment with reference to published criteria; and minimization ofed bias 
by using outcomes that were rated and adjudicated independently of the doctors caring for these 
adults in clinical practice. The clinical outcome and proportions of bAVM obliterated by treatment 
in Scotland appear generalizable, by being at least as good as reports in systematic reviews6 and 
the USA Nationwide Inpatient Sample database.28 Furthermore, the rate of hemorrhage from 
unruptured bAVMs (18%, 95% CI 11-30 after 12 years; Figure 3) was consistent with reported 
rates.1 We maximized sample size by including all adults newly diagnosed with a bAVM in an adult 
population of 4.3 million over one decade and outcome events to power multivariable analyses of 
the primary and secondary outcomes (Table 2). 
 
Our comparison of bAVM treatment and conservative management was not randomized, although 
we adjusted for known predictors of poor outcome and baseline imbalances. Both the robustness 
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of our findings in sensitivity analyses, as well as consistency between our findings and ARUBA,27 
and between observational studies and randomized trials in general,15,16 is reassuring. The primary 
outcome did not include the baseline measurement of handicap (and therefore allowed recovery 
from initial presentation) and crucially it allowed for recovery from the known early 
complications after bAVM treatment by requiring handicap to be sustained for at least two 
successive years. However, functional outcome measures are affected by both consequences of 
bAVMs and their treatment, as well as other co-morbidities. The primary outcome was difficult to 
interpret beyond four years, because of the frequency of bAVM-unrelated deaths, which were 
attributable to the imbalance in age between the groups at baseline and in turn led to the 
proportional hazards assumption being violated thus precluding adjustment. 
 
Our findings urge caution about treating unruptured bAVMs. Patients’ decisions can be guided by 
the absolute risks and relative effects in this observational study, the ARUBA trial,27 systematic 
reviews,1,6 and patients’ personal preferences. There has long been uncertainty about the best 
management of unruptured bAVMs29 and this is likely to continue until participants are followed 
for most of their lifetimes to see if the beneficial effects of conservative management are 
sustained. 
Formatted: Font: Bold
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FIGURE 1 – Flowchart of included participants. 
bAVM = arteriovenous malformation 
* Five patients experiencing bAVM hemorrhage during conservative management subsequently 
had bAVM treatment, but remained in the conservative management group for analysis of the 
primary outcome 
Resident in Scotland and aged at least 16 
years at the time of a first-in-a-lifetime 
definite diagnosis of an unruptured brain 
arteriovenous malformation (bAVM) [n=213] 
 
First diagnosed at autopsy [n=4] 
History of symptomatic spontaneous intracranial hemorrhage, 
which was anatomically consistent with bAVM location, before 
the clinical presentation which led to bAVM diagnosis [n=5] 
Eligible participants [n=204] 
Treatment of a 
bAVM or associated 
aneurysm [n=103] 
Conservative 
management 
[n=101] 
Follow-up for secondary 
outcomes [n= 103] 
Follow-up for primary 
outcome [n=98] 
Secondary outcomes [n=38] 
o Intracranial hemorrhage 
(17), cerebral infarct (6), 
non-hemorrhagic focal 
neurological deficit (15) 
 bAVM/aneurysm (10) 
 Treatment (28) 
Primary outcome [n=49] 
o Death (31) 
 bAVM/aneurysm (6) 
 Other (20) 
 Possibly bAVM (5) 
o Non-fatal handicap (18) 
Follow-up for primary 
outcome [n=103] 
Primary outcome [n=48] 
o Death (10) 
 bAVM/aneurysm (2) 
 Other (6) 
 Possibly bAVM (1) 
 Treatment (1) 
o Non-fatal handicap (38) 
Follow-up for secondary 
outcomes [n= 101] 
Secondary outcomes [n=13] 
o Intracranial hemorrhage 
(13),* cerebral infarct (0), 
non-hemorrhagic focal 
neurological deficit (0) 
 bAVM/aneurysm (13) 
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TABLE 1 – Baseline characteristics of adults with a definite diagnosis of a brain arteriovenous 
malformation (bAVM). 
 Conservative 
management 
 
(n=101) 
Treatment of 
bAVM or 
associated arterial 
aneurysm 
(n=103) 
Female  39 (39%)  44 (43%) 
Age at inception (mean ± SD), years***  53 ± 16  41 ± 13 
Mode of presentation**   
 Incidental  61 (60%)  40 (39%) 
          Seizure(s)  33 (33%)  52 (50%) 
           First seizure  15    26  
  Epilepsy  18    26  
 Focal neurological deficit  7 (7%)  11 (11%) 
Oxford Handicap Scale (OHS) 0-1 at presentation  61 (60%)  69 (67%) 
bAVM nidus location   
 Brainstem  3 (3%)  1 (1%) 
 Cerebellum  1 (1%)  2 (2%) 
 Deep  3 (3%)  7 (7%) 
 Lobar  94 (93%)  93 (90%) 
Eloquent bAVM nidus location  50 (50%)  54 (52%) 
Maximum bAVM nidus diameter (n=182) **   
 <3cm  45 (51%)  50 (54%) 
 3-6cm  36 (40%)  43 (46%) 
 >6cm  8 (9%)  0 (0%) 
Catheter angiogram done (n=142) ***  46 (46%)  96 (93%) 
Venous drainage pattern (n=142)   
 Superficial  30 (65%)  69 (72%) 
 Both deep and superficial  13 (28%)  20 (21%) 
 Exclusively deep  3 (7%)  7 (7%) 
Spetzler-Martin Grade20 (n=142)   
 I  9 (20%)  21 (22%) 
 II  15  (33%)     36 (38%) 
 III  12  (26%)     29 (30%) 
 IV  8  (17%)     10 (10%) 
 V  2  (4%)  0 (0%) 
Co-existing intracranial aneurysms   
 Associated only  20 (20%)  19 (18%) 
 Remote and associated  1 (1%)  6 (6%) 
 Remote only  4 (4%)  2 (2%) 
 * P<0.05, ** P<0.01, *** P<0.001 
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FIGURE 2 – Progression to primary outcome (first occurrence after inception of death or 
handicap [Oxford Handicap Scale Score 2-5] sustained for two or more successive years) during 
12 years of prospective follow-up. 
Error bars represent the 95% confidence intervals of the cumulative proportions at four and 12 
years after inception. 
 
 
 
 
 
 
 
Adults at risk 
(events in 
preceding year) 
Treatment   103 72 (30) 60 (6) 53 (1) 45 (2) 39 (2) 34 (4) 31 (2) 27 (0) 23 (1) 19 (0) 16 (0) 7 (0) 
Conservative 101 90 (8) 71 (18) 56 (7) 44 (3) 35 (3) 28 (1) 23 (3) 21 (1) 18 (3) 11 (2) 9 (0) 6 (0) 
Log Rank (Mantel-Cox) chi-square=0.01, p=0.91 
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FIGURE 3 – Progression to secondary outcome (first occurrence after inception of a non-fatal 
intracranial hemorrhage, cerebral infarct, or persistent/progressive non-hemorrhagic focal 
neurological deficit, or death, due to a brain arteriovenous malformation [bAVM], associated 
arterial aneurysm or treatment complication) during 12 years of prospective follow-up. 
Error bars represent the 95% confidence intervals of the cumulative proportions at four and 12 
years after inception. 
  
Adults at risk 
(events in 
preceding year) 
Treatment   103 73 (28) 64 (6) 57 (1) 50 (1) 45 (1) 41 (0) 37 (1) 34 (0) 30 (0) 22 (0) 18 (0) 8 (0) 
Conservative 101 96 (1) 86 (6) 73 (3) 61 (1) 53 (1) 42 (0) 36 (1) 33 (0) 28 (1) 21 (0) 15 (0) 11 (0) 
Log Rank (Mantel-Cox) chi-square=15.45, p<0.001 
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TABLE 2 – Bivariate and multivariable Cox proportional hazards analyses of the first occurrence of a primary or secondary outcome. 
 
 Primary outcome 
(first occurrence during four years of follow-up after inception of 
death or handicap [Oxford Handicap Scale Score (OHS) 2-5] 
sustained for two or more successive years) 
 Secondary outcome 
(first occurrence during 12 years of follow-up after inception of a 
non-fatal intracranial hemorrhage, cerebral infarct, or persistent / 
progressive non-hemorrhagic focal neurological deficit, or death, 
due to a brain arteriovenous malformation [bAVM], associated 
arterial aneurysm or treatment complication) 
 Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
 Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
     Unadjusted 
bivariate 
Multivariable 
adjusted* 
     Unadjusted 
bivariate 
Multivariable 
adjusted§ 
Intervention              
 bAVM/aneurysm 
 treatment 
103  39  1.00 (reference) 1.00 (reference)  103  38  1.00 (reference) 1.00 (reference) 
 Conservative 
 management 
98  36  0.82 (0.52-1.29) 0.59 (0.35-0.99)  101  13  0.31 (0.17-0.58) 0.37 (0.19-0.72) 
Other covariates              
 Age at inception 
 (per year increase) 
201  75  1.01 (0.99-1.03) 1.01 (0.99-1.03)  204  52  0.98 (0.96-0.99) 0.99 (0.97-1.01) 
 Seizure(s) versus 
 other mode of 
 presentation 
201  75  1.04 (0.66-1.65) 0.74 (0.43-1.29)  204  52  1.42 (0.82-2.44) 1.21 (0.68-2.16) 
 Deep versus other 
 bAVM location 
201  75  0.75 (0.24-2.39) 0.73 (0.23-2.39)  204  52  1.99 (0.79-5.01) 1.71 (0.66-4.46) 
 OHS score 2-5 
 versus 0-1 at 
 presentation 
201  75  2.23 (1.41-3.50) 2.48 (1.49-4.12)  204  52  - - 
* adjusted for intervention, age at inception, mode of presentation, bAVM location, and OHS at presentation 
§ 
adjusted for intervention, age at inception, mode of presentation, and bAVM location 
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